Silence Therapeutics (SLN)
(Delayed Data from NSDQ)
$18.27 USD
-0.04 (-0.22%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $18.33 +0.06 (0.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SLN 18.27 -0.04(-0.22%)
Will SLN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SLN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLN
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
SLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
Other News for SLN
Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'
Silence: Additional siRNA Drug Data Leads To Next Stages Of Development
IN BRIEF: Logistics Development requested to convene general meeting
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Pharvaris (PHVS) and Stevanato Group (STVN)